Marvel Biosciences Gets $600K Alberta Innovates Funding

Marvel Biosciences Corp. secured non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support Phase I testing of its lead compound, MB-204. The AICE-funded project is worth $600,000 and is intended to offset a significant portion of the overall Phase I clinical trial cost.

The company said the AICE program is highly competitive and peer-reviewed, providing third-party validation for MB-204’s scientific and commercial potential. Marvel also referenced a separate grant from Canada’s NRC IRAP for development of a novel small-volume, liquid-based formulation designed to be pediatric-friendly and improve compliance for patients who have difficulty swallowing.